메드팩토

235980KOSDAQ자연과학 및 공학 연구개발업

57.8 / 100

Reference Date: 2026-04-13

Financial Score21.0 / 40

News Sentiment18.8 / 25

Momentum8.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Slightly down 4.8% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Medfact is a biotech company established in 2013, specializing in the development of innovative drugs for refractory cancers using advanced genomic analysis technology. Its flagship product, Vactosertib, targets the TGF-β1 signaling pathway to modulate the tumor microenvironment and enhance the efficacy of existing cancer treatments when used in combination. The company is currently conducting clinical trials for various cancers, including colorectal, pancreatic, and osteosarcoma.

Number of Employees

54people

Average Salary

57.3M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 120.074.0Point

PBR

3.85Industry Average 3.822.5Point

Higher than industry avg (caution)

ROE

-24.70Industry Average -32.113.5Point

Below industry avg

Debt Ratio

2.86Industry Average 7.526.5Point

Half of industry avg (excellent)

Trend 2023~20254.5 / 10 points

Revenue Growth Rate

1.5 / 3

Operating Profit Growth Rate

3.0 / 3

Avg ▲29.9% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -41.5% (improving, 3yr)

Detailed News Sentiment

2 totalPositive 1Neutral 1Negative 0Average Sentiment Score 75

Neutral
[임상 업데이트] 이엔셀, ‘EN001’ 1b상 반복투여 성공
이엔셀이 차세대 줄기세포 치료제 'EN001'의 임상 1b상 반복투여에서 우수한 내약성을 확인했다는 내용으로, 메드팩토와 직접적인 관련은 없습니다.
Positive
메드팩토, AACR서 대장암 삼제병용 전임상 성과 발표
메드팩토가 AACR에서 항암제 후보물질 '백토서팁'의 대장암 삼제 병용요법 전임상 성과를 발표하며 높은 종양억제율과 완전관해율을 보였습니다.

Detailed Momentum

52-week position5.0Point

52w mid range (42%)

Current 5,170Won52-week high 8,05052-week low 3,065

1-month return2.0Point

1m -4.79% (slight drop)

Volume trend1.0Point

Volume dry-up

Detailed Disclosure

9 totalPositive 0Neutral 9Negative 0

Neutral[기재정정]주식매수선택권부여에관한신고2026-03-26
Neutral[기재정정]주식매수선택권부여에관한신고2026-03-26
Neutral[기재정정]주식매수선택권부여에관한신고2026-03-26
Neutral정기주주총회결과2026-03-26
Neutral주식매수선택권부여에관한신고2026-03-26